Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362301 | 1.00 | HSD17B10 (0.41) | HSD17B10HRH2HRH1LTA4HITGB3 | |
| SCHEMBL29954077 | 1.00 | HSD17B10 (0.41) | HSD17B10HRH2HRH1LTA4HITGB3 | |
| SCHEMBL29307370 | 0.88 | HSD17B10 (0.38) | HSD17B10ITGB3ITGA2BSMN1; SMN2ACE | |
| SCHEMBL188132 | 0.87 | HSD17B10 (0.48) | HSD17B10ITGB3ITGA2BALOX15SMN1; SMN2 | |
| SCHEMBL1644494 | 0.87 | HSD17B10 (0.48) | HSD17B10ITGB3ITGA2BALOX15SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL25226809 | 0.85 | HSD17B10 (0.47) | HSD17B10ITGB3ITGA2BALOX15SMN1; SMN2 | |
| SCHEMBL1063621 | 0.83 | KDM4E (0.45) | HRH2HRH1LTA4HSMN1; SMN2GNAI3 | |
| SCHEMBL1006226 | 0.83 | KDM4E (0.45) | HRH2HRH1LTA4HSMN1; SMN2GNAI3 | |
| SCHEMBL5848866 | 0.83 | KDM4E (0.45) | HRH2HRH1LTA4HSMN1; SMN2GNAI3 | |
| SCHEMBL12226501 | 0.82 | HRH2 (0.44) | HRH2HRH1LTA4HSMN1; SMN2GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | HSD17B10 3474/4885HRH2 333/4885HRH1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.